XAIR - Beyond Air, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Beyond Air, Inc.

825 East Gate Boulevard
Suite 320
Garden City, NY 11530
United States
516-665-8200
http://www.ait-pharm.com

Sector
Industry
Full Time Employees18

Key Executives

NameTitlePayExercisedYear Born
Mr. Steven Adam LisiCEO & Chairman450kN/A1971
Mr. Amir AvnielCo-Founder, Pres, COO & Director400kN/A1974
Mr. Douglas J. Beck CPAChief Financial Officer250kN/A1961
Mr. Adam NewmanChief Legal Officer & Gen. Counsel250kN/AN/A
Mr. Duncan FatkinChief Commercial Officer104.17kN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory tract infections and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. The company is based in Garden City, New York.

Corporate Governance

Beyond Air, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.